News Archive

SomaLogic announced today the names of the six scientists whose proposals were chosen to receive funding from the 2016 SOMAscan Biomarker Discovery Grant Program. Of the 62 entries received, these six were selected as the top proposals by a team of non-SomaLogic peer reviewers on the basis of scientific merit.

A study published online today in the Journal of the American Medical Association (JAMA) details the first successful effort to measure at scale the levels of more than a thousand proteins in blood in patients with coronary heart disease (CHD), and describes the identification of a combination of nine specific proteins whose levels taken together can accurately predict the risk of future heart attacks, strokes, heart failure or death. This 9-protein model is more accurate for predicting risk of such adverse events than any currently measured risk factors (e.g., cholesterol, blood pressure, diabetes, smoking or age). A diagnostic test based on these findings is in development for release later this year.

SomaLogic announced today that it has signed an agreement with University College London (UCL) to deploy SomaLogic’s proprietary SOMAscan assay in the UCL Genomics laboratory. This agreement marks the first placement of the assay in the University of London large network of self-governing colleges and research institutes.

SomaLogic, Inc., and Visium Healthcare Partners, LP today announced that SomaLogic will receive up to $60.5 million through a combination of debt and equity financing from Visium. The proceeds will be used to support SomaLogic’s continued growth, including its primary focus on the development of novel life science tools and clinical diagnostics based on the Company’s proprietary proteomics technology. Specific terms of the agreement were not disclosed.

SomaLogic, Inc., announced today that Matthew (“Matt”) Norkunas, M.D., has joined the company as Chief Financial Officer (CFO). “We are excited that Matt has agreed to join us during this critical growth period for SomaLogic,” said Byron Hewett, Chief Executive Officer. “His unique combination of experience and knowledge matches up well with our needs as we continue our transition from a start-up company to a successful business organization.”

The University of Oxford and SomaLogic announced today that they have agreed to undertake a number of collaborative projects that will employ SomaLogic’s proprietary SOMAmer reagents and SOMAscan assay technologies to discover and characterize protein biomarkers for a range of clinical diseases and conditions. In order to maximize the collaborative nature of these projects and accelerate the translation of discoveries into clinical testing, the agreement also includes the build-out of a SOMAscan assay service laboratory at Oxford under the direction of SomaLogic personnel.

SomaLogic announced today that it has signed an agreement with the Bristol-Myers Squibb Company (NYSE-BMY) to provide expanded access to its proprietary SOMAmer reagents. The agreement covers both the 1,310 reagents available in the current public version of the SOMAscan assay as well as custom SOMAmer reagents developed through SomaLogic’s SOMAmer Discovery Service specifically for Bristol-Myers Squibb. Specific terms of the agreement were not disclosed.

SomaLogic announced today that the Beth Israel Deaconess Medical Center in Boston, MA, is the latest academic center to deploy the SOMAscan assay in support of the protein biomarker discovery and development efforts of its research community. The SOMAscan assay will be performed under the leadership of Towia Libermann, PhD, Director of the BIDMC Genomics, Proteomics, Bioinformatics and Systems Biology Center and the Dana–Farber/Harvard Cancer Center (DF/HCC) Cancer Proteomics Core.

SomaLogic, Inc., and VU University Medical Center Amsterdam (VUmc), announced today that the SOMAscan® assay, a breakthrough proteomics platform, will be deployed at VUmc for its scientists’ use in multiple different biomedical research projects. The assay will be performed under the direction of Dr. Charlotte E Teunissen.

SomaLogic announced today that the U.S. Food and Drug Administration’s (FDA) National Center for Toxicological Research (NCTR) has reached an agreement with SomaLogic to deploy the SOMAscan proteomics assay in the NCTR’s research laboratories in Jefferson, AR. It is expected that the assay will be installed and fully functional at NCTR by early 2016.

In a “Fast Track” article published in the journal Nucleic Acid Therapeutics*, researchers from SomaLogic and Otsuka Pharmaceutical describe a series of studies that demonstrate that treatment with a novel Slow Off-rate Modified Aptamer (SOMAmer®) molecule can significantly delay the onset and reduce the severity of rheumatoid arthritis (RA) in a cynomolgus monkey model of the disease. The SOMAmer molecule used in these studies, named SL1026, was initially selected for its ability to directly bind and block the signaling of the critical inflammatory protein interleukin-6 (IL-6), which is known to be involved in RA onset and progression.

SomaLogic, Inc., announced today that its SomaLogic Clinical Laboratory (CLIA laboratory) has been registered with the Centers for Medicare and Medicaid Services (CMS) under the Clinical Laboratory Improvement Amendments of 1988, and has received accreditation by the College of American Pathologists (CAP).

SomaLogic was recognized as "Company of the Year" by the Colorado BioScience Association at its 12th Annual Awards Dinner in Denver, CO, on November 12, 2015. SomaLogic was cited for developing "a new proteomics technology with a mission to leverage its proprietary technology to discover, develop and commercialize revolutionary new life science research tools and breakthrough clinical diagnostic products that will transform healthcare." Chairman and Founder Larry Gold and CEO Byron Hewett accepted the award on behalf of the company and its 160 employees.
For more information, please visit the CBSA website.

SomaLogic announced today that the latest version of its proprietary SOMAscan proteomics assay, which now measures 1,310 protein analytes, is commercially available to the life science research community. Called “SOMAscan Assay 1.3k,” this new version is replacing the current 1,129-measurement version, but without an increase in price.

SomaLogic announced today that the University of Houston (Houston, TX) and Sidra Medical and Research Center (Doha, Qatar) are the latest academic centers to deploy SomaLogic’s proprietary SOMAscan assay to accelerate protein biomarker discovery and development across multiple life science research studies in their respective institutions.

SomaLogic, Inc., announced today that Otsuka Pharmaceutical Co., Ltd. has extended its initial collaboration agreement with SomaLogic to continue the development of several SOMAmer® therapeutics. Specific projects and financial terms in the extended agreement were not disclosed.

SomaLogic, Inc., announced today that it is making its proprietary SOMAmer® (Slow Off-rate Modified Aptamers) reagents commercially available as individual molecules to the life science and biopharma scientific communities for their specific protein-affinity research needs. The initial library available today includes 244 different SOMAmer reagents (and protein targets), and that number is expected to grow over the coming months.

Weill Cornell Medical College in Qatar (WCMC-Q) and SomaLogic announced today that the automated version of the SOMAscan assay, which has been previously available only at SomaLogic’s headquarters in Boulder, CO, will be installed at the WCMC-Q Education City campus in Doha, Qatar. In addition to being the first automated site outside of SomaLogic, this is also the first placement of the SOMAscan assay outside of North America.

The results of a collaborative study by a large group of academic, industry and patient advocacy scientists to address the critical need for useful biomarkers to help with the diagnosis and treatment of Duchenne muscular dystrophy is published today in the Early Edition of the Proceedings of the National Academy of Sciences USA (PNAS). Using the SOMAscan assay to measure 1,125 proteins simultaneously in the blood of Duchenne patients and age-matched controls, the research group identified highly significant changes in the concentration levels of 44 different proteins. These findings are being shared openly with the entire Duchenne research and patient advocate community in the hope of driving further understanding of Duchenne biology, as well as accelerating new diagnostic and therapeutic development.

SomaLogic, Inc., announced today that the University of Manitoba’s Centre for Proteomics and Systems Biology (MCPSB) is the first SOMAscan™ assay “Early Access” site outside of the United States. It is expected that the assay will be installed and fully functional at the Centre by the middle of 2015, under the leadership of Director John A. Wilkins, Ph.D.

SomaLogic, Inc., announced today that the SOMAscan™ assay, a breakthrough proteomics platform, will be deployed at the University of Colorado Denver (UCD), Anschutz Medical Campus. The assay will be performed for UCD’s basic and clinical researchers under the direction of Mark Geraci, MD, Head of the Division of Pulmonary Sciences and Critical Care Medicine, and Bifeng Gao, PhD, Director and Manager of UCD’s Genomics and Microarray Core. It is expected that the SOMAscan assay will be installed and fully functional at UCD by early 2015.

SomaLogic announced today the launch of a new proteomics service offering aimed at providing its breakthrough protein-binding SOMAmer® reagents to the scientific community based on their specific needs in wide variety of different research uses. The SOMAmer Discovery Service team at SomaLogic will work closely with SomaLogic customers to develop and license “fit-for-purpose” SOMAmer reagents that strongly bind the customers’ proteins of interest, and function correctly in the particular assays they are performing with the reagents.

SomaLogic, Inc., announced today that Novartis has extended its multi-year research agreement for the development and application of SomaLogic’s unique proteomics technology to Novartis’ drug discovery and development efforts. Novartis will also take an equity position in SomaLogic under the agreement extension.

SomaLogic announced today that the National Institutes of Health (NIH) Center for Human Immunology, Autoimmunity and Inflammation (CHI) will use the SOMAscan™ proteomics assay for research with collaborators across the NIH. It is expected that the SOMAscan assay will be installed and fully functional at CHI by the beginning of 2015, under the leadership of CHI Director Neal S. Young, M.D.

Children’s Hospital Colorado and SomaLogic, Inc., announced today that they have entered into a collaborative agreement to discover protein biomarkers and use those biomarkers to develop laboratory tests to improve the diagnosis and management of childhood diseases. The discovery and development work will be done using SomaLogic’s novel proteomics SOMAscan™ assay, which can measure more than a thousand proteins in a small amount of blood or other biological samples. This innovative collaboration is being entered into as a result of successful initial exploratory research done by the two organizations.

SomaLogic, Inc. and NEC Corporation (TYO: 6701) announced today an agreement that gives NEC exclusive marketing rights in Japan for SomaLogic’s SOMAscan™ assay, which is built on SomaLogic’s proprietary SOMAmer® technology. Under the agreement, NEC will offer access to the SOMAscan assay to biopharmaceutical companies, food companies, and academic research centers for their research in Japan.

SomaLogic, Inc., announced today that Massachusetts General Hospital (MGH) will be the first Boston-area biomedical research center to perform on-site studies using the SOMAscan™ assay, a breakthrough proteomics platform that can measure more than a thousand proteins in a small amount of blood or other biological sample.

SomaLogic, Inc., announced today that Paul Menter has joined the company as Vice President & General Manager, Life Science Tools. In his new role, Paul will be responsible for overseeing the growth of SomaLogic’s current proteomics tools offerings, as well as the expansion in number and type of new tools available to life sciences researchers.

SomaLogic announced today that it is a launch partner of the Medical Research Council's (MRC) UK Dementias Research Platform (UKDP), a £16 million ($27 million) public-private partnership set up to speed up research into dementias. According to the MRC's press release, the collaboration aims to enable earlier detection, improved treatment and, ultimately, prevention of the disease, by looking not just at what is going wrong in the brain, but at the brain in the context of the whole body.

SomaLogic, Inc., announced today that the Perelman School of Medicine at the University of Pennsylvania is the first biomedical research center that will offer researchers on-site access to the SOMAscan™ assay, the most powerful proteomics platform available today. The assay will be performed at Penn’s Institute for Translational Medicine and Therapeutics (ITMAT), under the leadership of Daniel J. Rader, MD, associate director of ITMAT and chair of the Department of Genetics., and Stephen Master, MD, PhD,  assistant professor of Pathology and Laboratory Medicine and director of ITMAT’s Translational Core Laboratory. It is expected that the SOMAscan assay will be fully functional at Penn by midsummer 2014.

SomaLogic, Inc., announced today that it has received additional funding from the Bill & Melinda Gates Foundation to further develop and validate a SOMAmer-based tuberculosis (TB) biomarker assay for the accurate identification of persons with active TB. This new funding recognizes and extends the successful work completed under the initial TB biomarkers grant awarded to SomaLogic in January 2012 through the Bill & Melinda Gates Foundation's Grand Challenges in Global Health program. 

SomaLogic, Inc., announced today that Dan Muehl has joined the company as Chief Financial Officer (CFO). “I am delighted that Dan has agreed to join us during this critical growth period for SomaLogic,” said Byron Hewett, Chief Executive Officer. “His financial and personal skills are an ideal match for our culture and team, and for the challenging work ahead of us.”

In a pair of papers published in the Journal of Biological Chemistry on January 12, 2014, a group of SomaLogic researchers and their colleagues at Otsuka Pharmaceuticals and Emerald Bio describe the development of new SOMAmer reagents that can block signaling by interleukin-6 (IL-6, a critical protein involved in inflammation and cancer), as well as the structural interaction of the two molecules. This work both confirms the unique protein-binding properties of SOMAmers and underlines their potential as a new class of therapeutic reagents.

The Board of Directors of SomaLogic Inc. (a privately held biotechnology company) announced today that Byron Hewett has been appointed as Chief Executive Officer (CEO), effective Dec 2, 2013. SomaLogic was founded in 2000 by its original  CEO, Larry Gold, who will continue as Chairman of the Board. Dr. Gold will also continue to work full time at SomaLogic, advising the new CEO and other senior management leaders. 

Agilent Technologies SomaLogic announced today that they have entered into an agreement to expand access to SomaLogic’s unbiased protein biomarker discovery platform. The companies will work together to place SomaLogic’s SOMAscan proteomic assay, which employs custom Agilent microarrays in its workflow, in select academic and contract research centers. This effort will help meet the rapidly growing demand for access to SomaLogic’s highly multiplexed, cost-effective proteomic platform, and expand Agilent's presence in the proteomics market. 

In an interview published June 10th in CEOCFO Magazine, SomaLogic Chairman and CEO Larry Gold describes the company's mission and focus, and presents examples of current work being done.

In a scientific study published today in the journal Cell, a team of researchers led by scientists from the Harvard Stem Cell Institute and including scientists from SomaLogic, describe the discovery of a circulating protein, called GDF-11 (Growth Differentiation Factor 11), that can reverse age-related cardiac hypertrophy in mice. The GDF-11 protein was identified using SomaLogic's breakthrough SOMAscan proteomics technology.

A multi-institute team of researchers led by scientists at SomaLogic announced today the results of a study describing multiple blood-based protein biomarkers that more fully reveal the body’s response to pulmonary tuberculosis (TB) infection and its successful  treatment. Their work, which is based on the application of the SOMAscan™ assay, is published today in the open-access scientific journal PLOS ONE.

Academic scientists from major biomedical research institutions came together on March 25, 2013, to describe how they have applied SOMAscan to their efforts to find disease biomarkers in several types of cancer. The archived webinar is now available for viewing (following registration).

A February 7, 2013 webinar entitled "The Proteomics of Pulmonary Diseases" presented by SomaLogic scientists is now available for download for interested parties.

On February 1, 2013, the University of Colorado Boulder renamed its MCDB (Molecular, Cellular and Developmental Biology) building the “Gold Bioscience Building” in honor of SomaLogic CEO and Chairman Larry Gold. 

The molecular structure of a SOMAmer (Slow Off-rate Modified Aptamer) reagent bound to its specific protein has been revealed for the first time by a team of scientists from Emerald Bio and SomaLogic in a manuscript published online this week in the Proceedings of the National Academy of Science (PNAS). Their analyses demonstrate the molecular basis for the vast improvement in protein binding by SOMAmers as compared to traditional aptamers, emphasizing that SOMAmers represent an entirely new class of molecular “affinity reagents” with multiple useful applications in life sciences and medicine.

A multi-institute team of researchers led by scientists at the NYU Langone Medical Center and SomaLogic, Inc., announced today the discovery and validation of a panel of 13 blood-based protein biomarkers that can detect malignant mesothelioma in even the early stages of this rare but deadly cancer. The work, which is based on a new protein measurement technology developed by SomaLogic, is published today in the open-access scientific journal PLOS ONE.

The first commercially available laboratory-developed testing (LDT) testing service to use SomaLogic's SOMAmer protein measurement technology is now available through our collaborator, Quest Diagnostics, the world's leading diagnostic testing company. Quest incorporated the SOMAmer technology into its novel clinical testing service. This testing service measures free (i.e., not bound by drug) Epidermal Growth Factor Receptor, in patients receiving particular cancer treatments. Quest Diagnostics' clinical laboratory in San Juan Capistrano, CA, developed, validated and offers the testing service to clinicians in the United States. For more information, please visit Quest's website

SomaLogic, Inc., and NEC Corporation (NEC; TSE: 6701) today announced the release of SomaSuite, a professional software tool developed by NEC that provides simple, reliable and direct access to the highly multiplexed proteomic data generated by SomaLogic’s SOMAscan assay technology. SomaSuite Version 1.0 enables all clinical researchers, regardless of their level of bioinformatic expertise, to analyze the hundreds of measurements over thousands of proteins produced by the SOMAscan assay. SomaSuite provides an intuitive graphic display that enables researchers to quickly discover significant protein expression changes in their biological samples.

A novel application of SOMAscan™ technology identifies significant protein expression level differences in tumors vs. adjacent non-cancerous tissue, confirming known biomarkers and discovering new ones. In addition, SomaLogic scientists demonstrate the utility of SOMAmer binding reagents as tissue imaging probes.

HUNT Biosciences and SomaLogic, Inc., today announced a new collaboration to advance the clinical use of protein biomarkers, with an initial focus on the validation of biomarkers for the prediction of cardiovascular events such as strokes, heart attacks, and heart failure.

“Prediction” is only part of what is needed to realize the promise of personalized medicine: It is perhaps more critical to detect the early onset of disease in real time, when it is most likely to be successfully treated. Dr. Larry Gold, CEO of SomaLogic and Professor at the University of Colorado Boulder, presented SomaLogic's breakthrough SOMAscan proteomic technology – which promises to provide such sensitive and early detection, and ultimately transform the practice of medicine – at a special Session on “Predictive Medicine” on February 17, 2012, at the American Association for the Advancement of Science (AAAS) annual meeting in Vancouver, Canada.

With the recent successful commercial launch of its powerful protein biomarker SOMAscan™ assay as a service to biopharmaceutical researchers, SomaLogic scientists presented both the “nuts and bolts” of the technology as well as its multiple therapeutic and diagnostic applications to over 3000 participants at the 2012 Molecular Medicine Tri-Conference February 19-23 in San Francisco, CA.

SomaLogic, Inc., announced today that it will receive a tuberculosis (TB) biomarkers grant through the Bill & Melinda Gates Foundation’s Grand Challenges in Global Health program, an initiative that seeks to overcome persistent bottlenecks in creating new tools that can radically improve health in the developing world. Urs Ochsner, head of the Infectious Diseases Research Group at SomaLogic, will pursue an innovative research project to identify and validate TB biomarkers, titled SOMAmer-based detection of tuberculosis biomarkers.

SomaLogic and Novartis have entered into a multiyear research collaboration to bring SomaLogic's proteomic technology to bear on accelerating Novartis' research and development efforts, by identifying novel biomarkers, therapeutic targets, and physiological effects of potential new drugs. The agreement includes the potential for joint development of companion diagnostics arising from the collaborative effort.

SomaLogic, Inc. and New England Biolabs, Inc. (NEB) announced today that they have entered into an exclusive licensing agreement whereby SomaLogic will provide specific SOMAmers as critical and unique reagents in several current and future NEB nucleic acid amplification and polymerase chain reaction (PCR) products.

Even with astounding advances in genomic science, genetic analysis of disease remains largely a measure of risk rather than actual disease state. A truer and more immediate measure of health can be obtained by analysis of proteins, especially those that are “biomarkers” of disease state.

Emerald BioStructures, a leading provider of integrated structural biology services, and SomaLogic, Inc., a diagnostics and biomarker discovery company, today announced that they have entered into a strategic collaboration for the structure-based design of chemically modified DNA aptamers (“SOMAmers”) and small molecule therapeutics, based on crystal structures of important protein targets bound to high affinity SOMAmers.

NEC Corporation (NEC) and privately held SomaLogic, Inc. announced today that they have signed an agreement to explore aptamer-related businesses in the life sciences and healthcare markets. In addition, NEC announced that it has made an equity investment in SomaLogic in support of a long-term strategic relationship between the two companies.

SomaLogic, Inc. announced today that SomaLogic and Otsuka Pharmaceutical Co., Ltd. entered into a collaboration agreement to use SomaLogic's proprietary aptamer technology to discover and develop novel diagnostic products and to design research tools that will enhance Otsuka's pharmaceutical discovery and development efforts.

SomaLogic, Inc., a leading clinical proteomics company, today announced that it had entered a technology development agreement with Quest Diagnostics Incorporated (NYSE: DGX), the leading provider of diagnostic testing, information and services in the U.S. Under the terms of the agreement, Quest Diagnostics will develop new diagnostic tests based on SomaLogic's proprietary aptamer array platform.